Everest Medicines Limited (HKG:1952)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 12.58B |
| Revenue (ttm) | 932.82M |
| Net Income (ttm) | -721.85M |
| Shares Out | 353.29M |
| EPS (ttm) | -2.23 |
| PE Ratio | n/a |
| Forward PE | 247.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,000 |
| Average Volume | 2,443,292 |
| Open | 35.50 |
| Previous Close | 35.60 |
| Day's Range | 35.50 - 36.56 |
| 52-Week Range | 33.22 - 77.55 |
| Beta | 1.80 |
| RSI | 42.22 |
| Earnings Date | Mar 27, 2026 |
About Everest Medicines
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam... [Read more]
Financial Performance
In 2024, Everest Medicines's revenue was 706.68 million, an increase of 461.16% compared to the previous year's 125.93 million. Losses were -1.04 billion, 23.3% more than in 2023.
Financial numbers in CNY Financial StatementsNews
Everest Medicines Advances With Major Licensing Deal, New Drug Application Approval
Everest Medicines Ltd. (1952.HK) last Thursday announced an exclusive licensing agreement to commercialize Micot's MT1013 for the treatment of secondary hyperparathyroidism (SHPT), worth up to 1.24 bi...
AI-powered Cancer Vaccine In The Works
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine's EVM14 cancer vaccin...
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first half 2025 PALIZADE Phase 2b clinical trial of ...